Average LDL-C reduction with lipid-lowering therapies (ESC/EAS):
■ Statins are the foundation:
Moderate-intensity ≈ 30%
High-intensity ≈ 50%
■ Statin + non-statin combinations markedly improve efficacy:
High-intensity statin + ezetimibe ≈ 60%
High-intensity statin + bempedoic acid ≈ 58%
■ PCSK9 inhibitors provide the largest incremental effect:
PCSK9 mAb alone ≈ 60%
With statins ± ezetimibe → 75–80%
■ Maximal LDL-C lowering (~85–86%) is achieved with quadruple therapy
(high-intensity statin + ezetimibe + bempedoic acid + PCSK9 mAb).
■ Clinical implication: very-high-risk patients usually require early combination therapy to reach ESC LDL-C targets.
#medical #cardiology #hearthealth #heart #fblifestyle

Comments
Post a Comment
Drop your thoughts here, we would love to hear from you